When four Medicare Administrative Contractors (MACs) publish nearly identical educational articles on the same topic within a short timeframe, it’s worth asking why.
That is exactly what recently occurred with the Medicare date-of-service (DOS) policy. Novitas Solutions, Palmetto GBA, First Coast Service Options, and CGS Medicare each released updated educational guidance explaining the longstanding Medicare DOS requirements for clinical laboratory testing.
At first glance, the articles may appear to introduce new policy. They do not.
The underlying CMS regulations remain unchanged. The 14-day rule, the molecular pathology exceptions, advanced diagnostic laboratory test (ADLT) provisions, and the general principles governing laboratory billing have not been revised.
What has changed is the emphasis.
A shift from regulation to operational compliance
Rather than announcing new reimbursement requirements, the MACs are reinforcing consistent operational interpretation of existing regulations. This coordinated effort reflects an increasing focus on billing accuracy, documentation, and audit readiness.
For laboratories, this distinction is important.
Many organizations have built their billing workflows around the Medicare DOS regulations for years. However, inconsistent interpretation of those rules—particularly among referring providers, hospital outreach programs, pathology groups, and reference laboratories—continues to generate claim denials, payment delays, and compliance risk.
The MACs appear to be addressing those operational inconsistencies before they become larger audit concerns.
The most significant clarification: defining the ‘date test performed’
Perhaps the most noteworthy clarification is the MACs’ explanation of what constitutes the “date the test is performed” when a Medicare DOS exception applies.
The updated guidance identifies the laboratory report date as the operative date used for determining when certain tests qualify for separate billing under the Clinical Laboratory Fee Schedule.
While this interpretation aligns with existing CMS policy, many laboratories have historically relied on other operational milestones, including instrument completion, technical analysis, or result verification.
By explicitly connecting the “date test performed” to the report date, the MACs have provided laboratories with a clearer operational standard that should be reflected consistently in laboratory information systems, documentation, and billing workflows.
Documentation is becoming just as important as billing
Another notable theme throughout the updated guidance is documentation.
Historically, Medicare DOS education focused primarily on determining which date should be billed. The new articles devote considerably more attention to documenting how that determination was made.
Laboratories should ensure they can clearly demonstrate:
- The specimen collection date
- The laboratory report date
- Whether the patient encounter was inpatient or outpatient
- Why a DOS exception applies, when applicable
This information may already exist within laboratory or pathology reports, but organizations should evaluate whether it is consistently documented and readily available during an audit.
Increasingly, Medicare expects organizations not only to bill correctly but also to demonstrate why the claim was billed correctly.
Understanding the patient encounter has never been more important
One of the recurring themes across all four MAC publications is the importance of correctly identifying the patient’s encounter status.
Whether the specimen originated during an inpatient admission, outpatient hospital visit, or non-patient encounter directly affects who is responsible for billing Medicare.
For independent laboratories receiving specimens from multiple hospital systems, this distinction can be difficult to identify. Nevertheless, incorrect assumptions remain one of the most common contributors to Medicare DOS billing errors.
The updated educational articles place greater emphasis on obtaining accurate encounter information before claims are submitted.
A welcome addition: practical decision trees
One of the strongest enhancements in the revised educational materials is the inclusion of decision trees that guide laboratories through common Medicare DOS scenarios.
Rather than relying solely on regulatory language, the visual workflows help organizations determine whether the hospital or laboratory should bill Medicare and whether a DOS exception applies.
These tools should prove particularly valuable for educating billing teams, compliance staff, and new laboratory personnel.
What these updates indicate for the lab industry
Viewed collectively, these publications suggest more than a routine educational update.
The coordinated messaging across multiple MACs reflects an industry-wide effort to standardize interpretation of one of Medicare’s more operationally complex laboratory billing policies.
Although the regulations themselves have not changed, expectations surrounding documentation, consistency, and audit preparedness continue to evolve.
For laboratory leaders and billing teams, this is an opportunity to proactively evaluate internal processes rather than waiting for denials or audit findings to expose operational gaps.
Organizations should consider reviewing:
- Laboratory information system workflows supporting date-of-service determination
- Billing procedures for molecular pathology and other DOS exception testing
- Documentation practices supporting report dates and encounter status
- Staff education on Medicare DOS requirements
- Internal compliance audits focused on DOS accuracy
Successful reimbursement depends on consistent processes
As molecular diagnostics continue to expand and increasingly complex testing moves outside traditional hospital laboratories, accurate application of the Medicare DOS policy will remain a foundational component of compliant billing.
The recent MAC publications serve as a reminder that successful reimbursement depends not only on understanding the regulations, but also on implementing consistent operational processes that support them.
For laboratories, the message is clear: The policy hasn’t changed, but Medicare’s expectations for demonstrating compliance continue to mature. Organizations that invest now in education, documentation, and standardized workflows will be better positioned to reduce denials, withstand audits, and support long-term revenue integrity.